Lavandula angustifolia is a plant of Lamiaceae family, with many therapeutic properties and biological activities, such as anticonvulsant, anxiolytic, antioxidant, anti-inflammatory, and antimicrobial activities. The aim of this study was to evaluate the effect of Lavandula angustifolia Mill. essential oil (LEO) on acute inflammatory response. LEO was analyzed using gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance spectroscopy (NMR) methods and showed predominance of 1,8-cineole (39.83%), borneol (22.63%), and camphor (22.12%). LEO at concentrations of 0.5, 1, 3, and 10 μg/ml did not present in vitro cytotoxicity. Additionally, LEO did not stimulate the leukocyte chemotaxis in vitro. The LEO topical application at concentrations of 0.25, 0.5, and 1 mg/ear reduced edema formation, myeloperoxidase (MPO) activity, and nitric oxide (NO) production in croton oil-induced ear edema model. In carrageenan-induced paw edema model, LEO treatment at doses of 75, 100, and 250 mg/kg reduced edema formation, MPO activity, and NO production. In dextran-induced paw edema model, LEO at doses of 75 and 100 mg/kg reduced paw edema and MPO activity. In conclusion, LEO presented anti-inflammatory activity, and the mechanism proposed of LEO seems to be, at least in part, involving the participation of prostanoids, NO, proinflammatory cytokines, and histamine.

Objetivou-se descrever as taxas de mortalidade e sobrevida de idosos com insuficiência cardíaca que fizeram uso de digoxina, bem como identificar os fatores de risco associados à mortalidade. Prontuários de pacientes idosos (≥60 anos) atendidos no ambulatório de cardiologia para insuficiência cardíaca e que fizeram uso de digoxina foram triados e selecionados para este estudo retrospectivo. Variáveis sociodemográficas e clínicas foram mensuradas. A sobrevida foi verificada pelas curvas de Kaplan-Meier e teste log-rank. A regressão logística múltipla ajustada foi utilizada para avaliar os potenciais fatores de risco associados à mortalidade. Dos 65 prontuários analisados a sobrevida foi menor nos pacientes que utilizavam a dosagem de 0,125mg (p=0,093). A taxa de mortalidade foi de 35,9% e as chances de óbitos aumentaram nos indivíduos com idade acima de 76 anos (p=0,010; ORaj: 4,021), que possuíam outras doenças cardíacas (p=0,004; ORaj: 5,943) e com maior tempo de uso da digoxina (p=0,047; ORaj: 1,164).Descritores: Digoxina, Mortalidade, Idoso. Mortality of digoxin-treated elderly cardiac subjectsAbstract: This study aimed to describe the mortality and survival rates of elderly with heart failure who used digoxin, as well as to identify the risk factors associated with mortality. Records of elderly patients (≥60 years old) treated at the heart failure outpatient cardiology clinic were screened and selected for this retrospective study. Sociodemographic and clinical variables were measured. Survival was verified by Kaplan-Meier curves and log-rank test. Adjusted multiple logistic regression was used to assess potential risk factors associated with mortality. Of the 65 medical records analyzed, survival was lower in patients using 0.125 mg (p=0.093). The mortality rate was 35.9% and the chances of death increased in individuals over the age of 76 years (p=0.010; ORaj: 4.021), who had other heart disease (p=0.004; ORaj: 5.943) and with longer use of digoxin (p=0.047; ORaj: 1.164).Descriptors: Digoxin, Mortality, Aged. Mortalidad de ancianos cardiacos tratados con digoxinaResumen: El objetivo es describir las tasas de mortalidad y supervivencia de personas mayores con insuficiencia cardíaca que usaban digoxina, así como identificar los factores de riesgo asociados con la mortalidad. Los registros de pacientes ancianos (≥60 años de edad) tratados en la clínica ambulatoria de cardiología con insuficiencia cardíaca se examinaron para este estudio retrospectivo. Se midieron variables sociodemográficas y clínicas. La supervivencia se verificó mediante curvas de Kaplan-Meier y prueba de log-rank. Se utilizó la regresión logística múltiple ajustada para evaluar los posibles factores de riesgo asociados con la mortalidad. De los 65 registros médicos analizados, la supervivencia fue menor en los pacientes que utilizaron 0.125 mg (p=0.093). La tasa de mortalidad fue de 35.9% y las posibilidades de muerte aumentaron en personas mayores de 76 años (p=0.010; ORaj: 4.021), que tenían otras enfermedades cardíacas (p=0.004; ORaj: 5.943) y con uso más prolongado de digoxina (p=0.047; ORaj: 1.164).Descriptores: Digoxina, Mortalidad, Anciano.